Edition:
United States

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

26.80USD
4:01pm EDT
Change (% chg)

$0.39 (+1.48%)
Prev Close
$26.41
Open
$26.43
Day's High
$26.97
Day's Low
$26.39
Volume
1,504,369
Avg. Vol
1,821,294
52-wk High
$26.97
52-wk Low
$19.67

Latest Key Developments (Source: Significant Developments)

Boston Scientific announces positive results from the Reprise III clinical trial
Tuesday, 16 May 2017 06:47am EDT 

May 16 (Reuters) - Boston Scientific Corp :The Boston Scientific LOTUS™ valve system demonstrated superior efficacy to Corevalve® in global reprise III trial at one year.Boston Scientific Corp says LOTUS valve system also demonstrated non-inferiority to corevalve platform for primary safety endpoint.Boston Scientific - secondary endpoint demonstrated LOTUS valve system had lower rates of moderate to severe pvl occurrences compared to corevalve platform.Boston Scientific Corp - LOTUS valve system showed superiority over corevalve tavi system platform for primary effectiveness endpoint.  Full Article

Boston Scientific closes Symetis acquisition
Tuesday, 16 May 2017 01:15am EDT 

May 16 (Reuters) - Boston Scientific Corp ::Boston Scientific closes Symetis acquisition.To immediately begin selling Acurate TA and Acurate Neo/TF valve systems in Europe and other geographies outside of U.S..  Full Article

Boston Scientific announces results of study evaluating patients implanted with S-ICD System
Thursday, 11 May 2017 01:02pm EDT 

May 11 (Reuters) - Boston Scientific Corp ::Announced results from U.S. post-market approval study evaluating 'real-world' patients implanted with S-ICD System.Acute results for S-ICD System show therapy effectively terminated life-threatening heart arrhythmias in 98.7% evaluated patients.S-ICD System analysis also validated low complication rates, with a complication-free rate of 96.2 percent at 30 days post-procedure.  Full Article

Boston Scientific receives FDA approval for resonate family of high-voltage devices
Tuesday, 9 May 2017 06:30am EDT 

May 9 (Reuters) - Boston Scientific Corp : :Boston Scientific receives U.S. FDA approval for resonate™ family of high-voltage devices.Boston Scientific-FDA approval for resonate family of implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator systems.  Full Article

Boston Scientific reports Q1 GAAP EPS $0.21
Thursday, 27 Apr 2017 06:30am EDT 

April 27 (Reuters) - Boston Scientific Corp :Boston Scientific announces results for first quarter 2017.Q1 GAAP earnings per share $0.21.Sees FY 2017 revenue $8.8 billion to $8.9 billion.Q1 sales $2.16 billion.Sees FY 2017 GAAP earnings per share $0.81 to $0.86.Sees Q2 2017 GAAP earnings per share $0.18 to $0.21.Sees Q2 2017 sales $2.185 billion to $2.215 billion.Q1 adjusted earnings per share $0.29.Q1 interventional cardiology worldwide sales $605 million versus $560 million.Qtrly cardiac rhythm management worldwide sales $463 million versus. $433 million last year.Q1 earnings per share view $0.30, revenue view $2.08 billion -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $1.24, revenue view $8.77 billion -- Thomson Reuters I/B/E/S.Q2 earnings per share view $0.31, revenue view $2.21 billion -- Thomson Reuters I/B/E/S.  Full Article

Boston Scientific initiates global study to assess sudden cardiac arrest prevention therapy
Tuesday, 18 Apr 2017 04:15pm EDT 

April 18 (Reuters) - Boston Scientific Corp ::Boston Scientific initiates global study to assess sudden cardiac arrest prevention therapy in patients with diabetes who have previously experienced a heart attack.Boston Scientific - emblem mri s-icd system has been accepted for parallel review for new indication by fda, centers for medicare & medicaid services.Boston Scientific Corp- organizations will concurrently review madit s-icd trial data as well as other relevant information to determine fda approval.  Full Article

Boston Scientific CEO Michael Mahoney's FY 2016 total compensation was $12 mln vs $11.6 mln in FY 2015
Tuesday, 28 Mar 2017 05:31pm EDT 

Boston Scientific Corp :CEO Michael Mahoney's FY 2016 total compensation was $12.0 million versus $11.6 million in FY 2015 - sec filing.  Full Article

German patent court issues initial decision
Thursday, 9 Mar 2017 06:35am EST 

Edwards Lifesciences Corp - : District court in Germany ruled that Boston Scientific's lotus valve infringes one of co's patents for transcatheter aortic valves . Edwards is not updating its 2017 financial guidance . Does not presently anticipate disruption to supply of sapien 3 valves to patients . Court also ruled Edwards Sapien 3 valve infringes two of Boston Scientific's patents for outer seals of transcatheter heart valves .Will promptly request an appeal.  Full Article

Boston Scientific receives favorable rulings in Edwards Lifesciences litigation
Thursday, 9 Mar 2017 04:59am EST 

Boston Scientific Corp : Boston scientific receives favorable rulings in edwards lifesciences litigation . German district court of Düsseldorf determined that Edwards Lifesciences infringed two patents of Boston Scientific . Edwards has stated that it will seek permission to appeal this judgment . Edwards Lifesciences and Boston Scientific can appeal each of four decisions as far as district court of Düsseldorf has decided against them .believes that '550 patent will be revoked by European patent office.  Full Article

Edwards Lifesciences says UK patent court issues decision on transcatheter heart valves
Friday, 3 Mar 2017 06:50am EST 

Edwards Lifesciences Corp : UK patent court issues initial decision . Edwards Lifesciences Corp says company is not changing its financial guidance . Edwards Lifesciences Corp - Edwards will promptly request an appeal on specific aspects of decision . Edwards Lifesciences-patents court in uk determined one of boston scientific's patents related to seals for transcatheter heart valves valve is invalid . Edwards Lifesciences Corp - court's decision does not affect commercial availability of sapien 3 valve . Edwards Lifesciences - boston scientific initiated litigation involves multiple patents in multiple venues, to yield court actions over extended period .Edwards Lifesciences Corp - patents court in uk has determined a second patent of Boston Scientific is valid and infringed.  Full Article

More From Around the Web

BRIEF-Boston Scientific announces positive results from the Reprise III clinical trial

* The Boston Scientific LOTUS™ valve system demonstrated superior efficacy to Corevalve® in global reprise III trial at one year